Self-Assessment Answers for Section 1: Effective Management of Acute and Chronic Pain with Opioid Analgesics
1 . Nonpharmacologic and self-management treatment options have been found to be effective alone or as part of a comprehensive pain management plan for which types of pain? 2 . What is the maximum recommended daily dose of acetaminophen for healthy adult patients? 3 . Which non-opioid analgesic has been successfully used to treat such acute pain conditions as sickle cell crises, renal colic, and trauma? 4 . Which of the following topics should be routinely covered as part of patient education about opioid analgesics? 5 . Which of the following is an example of a functional goal? 6 . Which of the following is a possible reason for prescribing naloxone to a patient who has been prescribed an opioid analgesic? 7 . According to the Centers for Disease Control and Prevention, what amount of opioid analgesic is appropriate for most painful conditions? 8 . Which of the following medications is a full mu-receptor agonist used to treat Opioid Use Disorder? 9 . Which of the following medications can be self-administered by patients with a medication obtained from a regular pharmacy? 10 . For which of the following must clinicians obtain a special waiver from the DEA prior to being able to prescribe the medication?
Self-Assessment Answers for Section 2: CDC Opioid Prescribing Guidelines for Chronic Pain
11 . What percentage of patients presenting to physician offices with non-cancer pain symptoms or pain-related diagnoses currently receive an opioid prescription in the US? 12 . The CDC guidelines (and others) define chronic pain as pain lasting more than _____or past the time of normal tissue healing. 13 . Although the terms “abuse,” “dependence,” and “addiction,” have been used in the past to describe a problematic pattern of opioid use leading to clinically significant impairment or distress, which term is now generally favored? 14 . Which statement best summarizes the CDC finding about opioids for chronic pain? 15 . How soon after starting a patient on opioid therapy should a clinician evaluate the risks and benefits of the treatment? 16 . What is one suggestion for a way to augment opioid treatment in order to help improve a patient’s pain and function? 17 . Which statement accurately describes a challenge clinicians face when considering initiating treatment with an opioid? 18 . Which of the following is not a key point for clinicians to discuss with patients when an opioid is prescribed? 19 . Why should ER/LA opioids be avoided when starting opioid therapy for chronic pain? 20 . At which level of opioid dosing should a clinician carefully reassess the evidence of benefits and risks for the patient? 21 . Most experts agree that opioid dosages should not be increased to _______without careful justification based on diagnosis and on an individualized assessment of benefits and risks. 22 . In general, the amount of opioids prescribed for acute pain should be limited to a day supply: 23 . Long-acting (LA) and extended-release (ER) formulations of opioids should typically not be used for treating which kind of pain? 24 . What is the initial suggested rate of taper for weaning patients safely off of an opioid? 25 . What do the CDC guidelines suggest regarding the prescription of opioids to pregnant women? 26 . For the treatment of chronic pain in patients with depression, which two classes of antidepressants are recommended? 27 . The DAST and AUDIT tools are examples of which kind of assessment? 28 . Which of the following is not a possible reason for prescribing naloxone to a patient who has been prescribed an opioid analgesic? 29 . How frequently should PDMP data be reviewed for patients on long-term opioid therapy? 30 . Which of the following is not a potential benefit of urine drug testing?
Self-Assessment Answers for Section 3: Evidence-Based Guidance on Prescribing Controlled Substances
31 . Under the Controlled Substances Act, the federal government considers cannabis: 32 . The Drug Enforcement Administration has named recurring patterns that might indicate inappropriate controlled substances (CS) prescribing, including which of the following? 33 . Attention deficit hyperactivity disorder is characterized by: 34 . Optimal treatment for narcolepsy: 35 . A common instruction to the patient contained in a treatment agreement for provision of opioids (or another CS) is: 36 . Patients with OUD or other problems managing opioids who are tapered or suddenly discontinued from opioids non-collaboratively are at risk for: 37 . Which medication should be withdrawn slowly over months when taper is indicated to prevent the possibility of hallucinations? 38 . The following FDA-approved medications to treat OUD are: 39 . Of the following choices, which drug has been identified by the Drug Enforcement Administration and the National Institute on Drug Abuse as having the highest potential for diversion? 40 . Which of the following is a measure to be enacted at a healthcare facility when diversion of CS by a healthcare worker is discovered?
Self-Assessment Answers for Section 4: Compassionate Care on the End-of-Life
41 . Roughly how many American adults have created an advance directive? 42 . How accurate are physicians, generally, in predicting patient preferences for end-of-life care? 43 . In the United States, what term is generally used for care of people who are not expected to live more than 6 months? 44 . The Karnofsky Scale may be useful for what clinical task? 45 . Which statement is true about the typical role of a referring physician relative to patients in hospice care? 46 . What condition do many older well adults consider as being “worse than death”? 47 . The opioids butorphanol, nalbuphine, and pentazocine, are not recommended in cancer pain management because ____________. 48 . Unwarranted fear of what potential side effect of opioid analgesics can lead to underprescribing by clinicians and/or under use by patients? 49 . Which class of adjuvant analgesic has received increasing attention in recent years as a possible way to control neuropathic pain? 50 . Which class of medications are first-line for treating dyspnea in end-of-life settings?